This is the first time a study describes how G-EYE® balloon technology correlates with Polyp Removal Time and Adenoma Detection Rate.
SMART Medical Systems’ G-EYE® Colonoscope is now FDA Cleared on Olympus’ PCF Colonoscope Series, Making it Available in the United States on the Commonly Used Models of All Leading Endoscopy Brands.
A recent article in Gastroenterology & Endoscopy News features SMART Medical’s G-EYE® balloon technology and its clinical benefits
Results from this randomized trial showed that the ADR, particularly for advanced and large adenomas, was substantially higher for the G-EYE®
SMART Medical has now commenced clinical collaboration with NYU Langone Health introducing its newly FDA-cleared G-EYE® 760 Colonoscope series.
New study confirms safety and efficacy of NaviAid™ AB.
SMART Medical's G-EYE® Colonoscope, incorporating the G-EYE® Balloon Technology to control the endoscope's field of view and positioning during colonoscopy, was cleared for marketing in the USA by the FDA.
This recent Network Meta-analysis is comparing very different modalities, attempting to increase Adenoma Detection Rates (ADR) in the colon. The detailed and comprehensive analysis concludes in a very thorough manner that no other product or tool can increase ADR the way the G-EYE® does.
SMART's G-EYE® 760R colonoscope, incorporating its G-EYE® Balloon Technology designed to increase the detection of cancerous polyps in colonoscopy, will become available by FUJIFILM Europe with its state-of-the-art ELUXEO system, as part of the newly formed strategic distribution partnership with FUJIFILM Corporation.
Improved Adenoma Detection Rate (ADR) substantiates G-EYE® colonoscopy as the preferable solution by not only increasing ADR but also reducing adenoma miss rates at the same time.
With 28% more adenomas detected than with conventional colonoscopes G-EYE® has the potential to become a standard of care in colonoscopy, not only for screening but also for indicated and index colonoscopies
At the BSG annual conference in Newcastle, PENTAX Europe used the event for the debut of its latest offering, the G-EYE® Pilot.
Professor Kiesslich published a 1,000 patient study in the March 2019 issue of the GIE journal
Brian Cochrane has been appointed to lead and spearhead the expansion of our business relations and commercialization efforts in the USA.